L & S Advisors Inc reduced its position in shares of Allergan PLC. (NYSE:AGN) by 9.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,049 shares of the company’s stock after selling 1,262 shares during the quarter. L & S Advisors Inc’s holdings in Allergan were worth $2,469,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Howard Hughes Medical Institute purchased a new position in shares of Allergan during the 2nd quarter valued at $103,000. Cable Hill Partners LLC grew its holdings in shares of Allergan by 255.2% during the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after acquiring an additional 370 shares in the last quarter. Rockefeller Financial Services Inc. grew its holdings in shares of Allergan by 283.7% during the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock valued at $111,000 after acquiring an additional 400 shares in the last quarter. Jacobi Capital Management LLC grew its holdings in shares of Allergan by 4.9% during the 1st quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after acquiring an additional 22 shares in the last quarter. Finally, Massey Quick & Co. LLC grew its holdings in shares of Allergan by 334.8% during the 2nd quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after acquiring an additional 385 shares in the last quarter. 81.34% of the stock is currently owned by institutional investors.
In other Allergan news, Chairman Brent L. Saunders purchased 4,600 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The stock was purchased at an average price of $164.74 per share, with a total value of $757,804.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christopher J. Coughlin purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 5th. The stock was acquired at an average cost of $163.30 per share, with a total value of $1,633,000.00. The disclosure for this purchase can be found here. 0.36% of the stock is currently owned by corporate insiders.
Allergan PLC. (AGN) opened at $168.00 on Thursday. The company has a market cap of $54,636.75, a PE ratio of 10.65, a PEG ratio of 1.10 and a beta of 1.11. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. Allergan PLC. has a 52-week low of $160.07 and a 52-week high of $256.80.
Allergan (NYSE:AGN) last announced its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, beating the Zacks’ consensus estimate of $4.06 by $0.09. The business had revenue of $4.03 billion during the quarter, compared to analyst estimates of $4.04 billion. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.32 earnings per share. sell-side analysts forecast that Allergan PLC. will post 16.28 EPS for the current fiscal year.
Allergan declared that its board has initiated a stock buyback program on Monday, September 25th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to buy up to 2.8% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its stock is undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Friday, November 17th will be given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.67%. The ex-dividend date of this dividend is Thursday, November 16th. Allergan’s dividend payout ratio is currently -12.44%.
A number of brokerages recently issued reports on AGN. Wells Fargo & Company reiterated an “outperform” rating and issued a $280.00 price objective (up from $270.00) on shares of Allergan in a report on Wednesday, August 9th. Morgan Stanley set a $200.00 price objective on shares of Allergan and gave the stock a “buy” rating in a report on Wednesday. Vetr cut shares of Allergan from a “strong-buy” rating to a “buy” rating and set a $187.73 price objective for the company. in a report on Wednesday. UBS reiterated an “outperform” rating and issued a $275.00 price objective on shares of Allergan in a report on Wednesday, August 9th. Finally, Argus reiterated a “buy” rating and issued a $280.00 price objective on shares of Allergan in a report on Monday, August 14th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the company. Allergan has an average rating of “Buy” and an average price target of $241.56.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.